IGF2BP3 and prostate carcinoma: We discovered that apart from 4 “readers” (YTHDC1, YTHDF2, YTHDF3 and IGF2BP3) whose mRNA expression level were insignificant differences in tumor and normal samples, mRNA expression of two “readers” (IGF2BP2 and METTL14) and two “writers” (VIRMA and ZC3H13) were lower in prostate cancer sites than in normal samples.